Revenue
2024
2025
LENZ Therapeutics, Inc. (LENZ)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | — | — | — | — |
| Research & development | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M | $9.1M |
| Operating expenses | — | $58.6M | $72.4M | $105.6M | $60.4M | $13.5M |
| Operating income | −$91.1M | −$58.6M | −$72.4M | −$105.6M | −$60.4M | −$13.5M |
| EBITDAderived | −$90.9M | −$58.6M | −$72.4M | −$103.3M | −$59.7M | −$13.4M |
| Net income | −$82.1M | −$49.8M | −$70.0M | −$101.1M | −$70.8M | −$68.4M |
| Basic EPSper diluted share | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
| Diluted EPSper diluted share | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 27, 2026Form 4 | George Jeffrey P.Director | BuyCommon Stock | 5.6K | $8.92 | $49.9K | 5.6K |
| Mar 27, 2026Form 4 | Schimmelpennink Evert B.President, CEO and Secretary | BuyCommon Stock | 28.1K | $8.95 | $251.4K | 77.3K |
| Mar 27, 2026Form 4 | Chevallard Daniel R.Chief Financial Officer | BuyCommon Stock | 7.5K | $8.57 | $64.3K | 12.9K |
| Nov 17, 2025Form 4 · 10b5-1 | Olsson ShawnChief Commercial Officer | SellCommon Stock | 5.8K | $26.37 | $152.6K | 4.7K |
| Nov 17, 2025Form 4 · 10b5-1 | Olsson ShawnChief Commercial Officer | SellCommon Stock | 4.2K | $25.74 | $108.4K | 10.5K |